Valproic acid in social phobla — An open trial

Nardi, AC; Mendlowicz, Mauro V.; Figueira, I.; Versiani, Márcio

doi:10.1016/s0006-3223(97)87395-7

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nardi et al treated 16 generalized social phobics in an open trial of valproate with doses of 500 to 1500 mg/day (mean dose ¼ 1071 AE 75 mg/day) for one to nine months. All patients were considered to be nonresponders (45). In another study, Kinrys et al treated 17 social phobics in a 12-week open trial of valproate with doses of 500 to 2500 mg/day (mean dose ¼ 1985 AE 454 mg/day).…”

Section: Valproatementioning

confidence: 99%

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Ameringen¹,

Mancini²,

Patterson³

et al. 2008

Medical Psychiatry

View full text Add to dashboard Cite

Section: Valproatementioning

confidence: 99%

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Ameringen¹,

Mancini²,

Patterson³

et al. 2008

Medical Psychiatry

View full text Add to dashboard Cite

“…Nardi et al [18] treated 16 patients with generalized social anxiety disorder in an open-label trial of valproic acid (500 to 1500 mg/d) for 1 to 9 months. All patients were considered nonresponders to valproic acid.…”

Section: Valproic Acidmentioning

confidence: 99%

Anticonvulsants in anxiety disorders

Kinrys

Wygant²

2005

Curr Psychiatry Rep

View full text Add to dashboard Cite

Anticonvulsant drugs have shown promising results in the treatment of mood disorders, leading to the investigation of their potential efficacy in other psychiatric disorders. Numerous case reports, open-label trials, and placebo- controlled trials investigating the use of anticonvulsants in the treatment of anxiety disorders have yielded broad and varying results. Generally, these studies have indicated a potential role for anticonvulsants in the treatment of anxiety as monotherapy or augmentation therapy; however, these early findings must be supported by additional investigation in large-scale, placebo-controlled studies. This article reviews past and current research being done in this novel area of psychopharmacology.

show abstract

Optimizing Treatment in Social Phobia: A Review of Treatment Resistance

Ameringen¹,

Mancini²,

Pipe³

et al. 2004

CNS spectr.

View full text Add to dashboard Cite

Over the last 25 years, there has been a rapid expansion of our knowledge base of social phobia (SP). Although there are a number of well-validated treatment modalities, including pharmacotherapy and cognitive-behavioral therapy, significant gaps remain in our ability to achieve full remission in most patients. Despite advances in the neurobiology of SP, the etiology has yet to be determined. Investigations examining potential predictors of response have provided little guidance in selecting an appropriate treatment modality. These gaps in our knowledge have pushed us to examine issues related to treatment resistance. This paper presents a review of the current literature and issues related to treatment-resistant SP, including a discussion of the functional impairment associated with SP, definitions of treatment response and remission, as well as outcome measures that have been used in clinical investigations of SP. In addition, criteria for a standard treatment trial, predictors of treatment response, a review of treatment resistance studies, and potential directions for future research are examined. The most promising strategies to attain remission, will likely involve augmenting selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors with agents such as anticonvulsants, benzodiazepines, and antipsychotics as well as combining pharmacotherapy with cognitive-behavioral therapy. Our current treatment target of simply attaining a response needs to be refocused, so that an asymptomatic state and high end state functioning become the final goal of treatment.

show abstract

Valproic acid in social phobla — An open trial

Cited by 4 publications

References 0 publications

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Anticonvulsants in anxiety disorders

Optimizing Treatment in Social Phobia: A Review of Treatment Resistance

Contact Info

Product

Resources

About